Europa Worldwide Group Enhances Carbon Management and Reporting With Blue Yonder
28.8.2025 09:00:00 CEST | Business Wire | Press release
Leading British LSP adopts accredited, precise emissions reporting to meet growing customer demand for more environmentally responsible operations
The global regulatory landscape, particularly in the U.K. and European Union, acts as a powerful catalyst for change, urging companies to embrace sustainable practices that extend beyond basic compliance. Logistics service providers (LSPs) are witnessing an increased demand from their customers to actively monitor emissions and ensure adherence to both current and forthcoming regulations. That’s why Europa Worldwide Group, a leading LSP with a global presence, has adopted Blue Yonder’s Logistics Emissions Calculator, part of the Sustainable Supply Chain Manager solution, to meet its sustainability goals and evolving customer demands.
Europa Worldwide, celebrated for its cutting-edge logistics solutions, has integrated Blue Yonder’s advanced logistics carbon management capabilities—recently enhanced by the acquisition of Pledge—across its Road Freight division in the U.K., Ireland, Belgium, and the Netherlands. This strategic implementation underscores the company's commitment to offering sustainable logistics services.
Europa Worldwide selected Blue Yonder for its ability to deliver precise and detailed carbon emissions reports, leveraging millions of data points through advanced emissions modelling. Blue Yonder’s Logistics Emissions Calculator provides GLEC-accredited and ISO 14083-aligned calculations, ensuring industry-recognized accuracy and credibility. Furthermore, Blue Yonder’s seamless API integration with Europa Worldwide’s transportation management system facilitates efficient carbon reporting, enhancing transparency and customer trust.
Prior to adopting Blue Yonder, Europa Worldwide faced challenges with its in-house emissions reporting method, which lacked the granularity and accreditation necessary for impactful sustainability efforts. The limitations of the previous system highlighted the need for a more robust solution to meet customer demands for precise data and to support the global initiative towards Net Zero.
“Europa Worldwide is proactively advancing towards more defined sustainability objectives,” said Tom Jenkins, Central Services Director, Europa Worldwide Group. “Since implementing Blue Yonder’s Logistics Emissions Calculator, we have experienced a significant rise in customer engagement with emissions reporting, showcasing the solution's value. The integration of Blue Yonder’s emission reporting capabilities underscores our dedication to maximizing strategic efforts in enhancing sustainability within logistics.”
The new reporting system was first launched in Europa Worldwide’s Road department, receiving significant usage by customers, with up to four new customers being added per week. Europa Worldwide plans to extend Blue Yonder’s Logistics Emissions Calculator to its Air and Sea customers by the end of 2025, further integrating emissions reporting into its customer self-serve portal for enhanced accessibility and self-service.
“Amidst a global push for sustainable practices, Europa Worldwide seized the opportunity to be a leader in addressing carbon emissions from logistics,” said Saskia Van Gendt, chief sustainability officer, Blue Yonder. “By strategically embedding sustainability into their operations, they are not only improving visibility for carbon emissions but also future proofing their business and their customers’ business against regulatory shifts. We are proud to support their journey towards decarbonizing transportation.”
Additional Resources:
- Learn more about Blue Yonder’s solutions for Logistics Service Providers
About Europa Worldwide Group
Europa Worldwide Group is an ambitious independent logistics operator with three divisions, Europa Road, Europa Air & Sea dedicated to getting goods from A to B on time, and Europa Warehouse, 3PL and warehousing experts who store, pack and dispatch goods for our customers. The group employs over 1,300 people globally with sites across the UK and Ireland, plus Europa’s own teams in Belgium, the Netherlands, France, Czech Republic, Hong Kong, China, India, the UAE and South Africa. The global operator has an annual turnover of £300m+. europa-worldwide.com
About Blue Yonder
Blue Yonder is the AI company for supply chain. As the world leader in end-to-end digital supply chain transformation, Blue Yonder offers a unified, AI-driven platform and multi-tier network that empowers businesses to operate sustainably, scale profitably, and delight their customers—all at machine speed. A pioneer in applying AI solutions to the most complicated supply chain challenges, Blue Yonder’s modern innovations and unmatched industry expertise help more than 3,000 retailers, manufacturers, and logistics service providers confidently navigate supply chain complexity and disruption. blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250828837213/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom